Single-centre, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Dose of 14C-labeled RO4917523 and an Intravenous Tracer Dose of 13C-labeled RO4917523 in Healthy Male Volunteers

Trial Profile

Single-centre, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Dose of 14C-labeled RO4917523 and an Intravenous Tracer Dose of 13C-labeled RO4917523 in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Basimglurant (Primary) ; Basimglurant (Primary)
  • Indications Fragile X syndrome; Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 15 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Planned End Date changed from 1 Jun 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 11 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top